Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection

ACS Nano

Volumn 6, Issue 1, 2012, Pages 696-704

  Xiao, Zeyu ^a,b   Levy Nissenbaum, Etgar ^a,b   Alexis, Frank ^a,b   Lupták, Andrej ^c   Teply, Benjamin A ^a,b   Chan, Juliana M ^b   Shi, Jinjun ^a,b   Digga, Elise ^a   Cheng, Judy ^a,b   Langer, Robert ^b   Farokhzad, Omid C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

aptamer; in vitro selection; internalization; nanoparticles; targeted cancer therapy

Indexed keywords

APTAMERS; CANCER CELLS; CANCER THERAPY; CELLULAR UPTAKE; CHEMOTHERAPEUTIC AGENTS; DIFFERENTIAL BINDING; DOCETAXEL; IN VITRO SELECTION; INTERNALIZATION; NON-TARGETED; PROSTATE CANCERS; PROSTATE CELLS; SELECTION PROCESS; SIZE MINIMIZATION; TARGET CELLS; TARGETED CANCER THERAPY; TARGETED NANOPARTICLE;

DISEASES; LIGANDS; NANOPARTICLES; ONCOLOGY; RNA;

CELLS;

APTAMER; NANOCAPSULE;

ARTICLE; CHEMISTRY; GENE THERAPY; GENETICS; HUMAN; MALE; METHODOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; GENE THERAPY; HUMANS; MALE; NANOCAPSULES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84856153806     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn204165v     Document Type: Article

References (41)

1. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle Therapeutics: An Emerging Treatment Modality for Cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
2. Langer, R. Drug Delivery and Targeting: Review Nature 1998, 392, 5-10
3. Farokhzad, O. C.; Cheng, J.; Teply, B. A.; Sherifi, I.; Jon, S.; Kantoff, P. W.; Richie, J. P.; Langer, R. Targeted Nanoparticle-Aptamer Bioconjugates for Cancer Chemotherapy in Vivo Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6315-6320
4. Sugano, M.; Egilmez, N. K.; Yokota, S. J.; Chen, F. A.; Harding, J.; Huang, S. K.; Bankert, R. B. Antibody Targeting of Doxorubicin-Loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Res. 2000, 60, 6942-6949
5. Sapra, P.; Allen, T. M. Internalizing Antibodies Are Necessary for Improved Therapeutic Efficacy of Antibody-Targeted Liposomal Drugs Cancer Res. 2002, 62, 7190-7194
6. Park, J. W.; Hong, K.; Kirpotin, D. B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U. B.; Marks, J. D.; Moore, D. Anti-Her2 Immunoliposomes: Enhanced Efficacy Attributable to Targeted Delivery Clin. Cancer Res. 2002, 8, 1172-1181
7. Whitehead, K. A.; Langer, R.; Anderson, D. G. Knocking down Barriers: Advances in SiRNA Delivery Nat. Rev. Drug Discovery 2009, 8, 129-138
8. Petros, R. A.; DeSimone, J. M. Strategies in the Design of Nanoparticles for Therapeutic Applications Nat. Rev. Drug Discovery 2010, 9, 615-627
9. Sawyers, C. L. The Cancer Biomarker Problem Nature 2008, 452, 548-552
10. Cao, Z.; Tong, R.; Mishra, A.; Xu, W.; Wong, G. C.; Cheng, J.; Lu, Y. Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes Angew. Chem., Int. Ed. 2009, 48, 6494-6498
11. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells Cancer Res. 2004, 64, 7668-7672
12. Bouchard, P. R.; Hutabarat, R. M.; Thompson, K. M. Discovery and Development of Therapeutic Aptamers Annu. Rev. Pharmacol. Toxicol. 2010, 50, 237-257
13. Keefe, A. D.; Pai, S.; Ellington, A. Aptamers as Therapeutics Nat. Rev. Drug Discovery 2010, 9, 537-550
14. Ellington, A. D.; Szostak, J. W. In Vitro Selection of RNA Molecules That Bind Specific Ligands Nature 1990, 346, 818-822
15. Tuerk, C.; Gold, L. Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase Science 1990, 249, 505-510
16. Daniels, D. A.; Chen, H.; Hicke, B. J.; Swiderek, K. M.; Gold, L. A Tenascin-C Aptamer Identified by Tumor Cell Selex: Systematic Evolution of Ligands by Exponential Enrichment Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 15416-15421
17. Shangguan, D.; Li, Y.; Tang, Z.; Cao, Z. C.; Chen, H. W.; Mallikaratchy, P.; Sefah, K.; Yang, C. J.; Tan, W. Aptamers Evolved from Live Cells as Effective Molecular Probes for Cancer Study Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11838-11843
18. Raddatz, M. S.; Dolf, A.; Endl, E.; Knolle, P.; Famulok, M.; Mayer, G. Enrichment of Cell-Targeting and Population-Specific Aptamers by Fluorescence-Activated Cell Sorting Angew. Chem., Int. Ed. 2008, 47, 5190-5193
19. Sefah, K.; Shangguan, D.; Xiong, X.; O'Donoghue, M. B.; Tan, W. Development of DNA Aptamers Using Cell-Selex Nat. Protoc. 2010, 5, 1169-1185
20. Xiao, Z.; Shangguan, D.; Cao, Z.; Fang, X.; Tan, W. Cell-Specific Internalization Study of an Aptamer from Whole Cell Selection Chemistry 2008, 14, 1769-1775
21. Wu, Y.; Sefah, K.; Liu, H.; Wang, R.; Tan, W. DNA Aptamer-Micelle as an Efficient Detection/Delivery Vehicle toward Cancer Cells Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 5-10
22. Pieken, W. A.; Olsen, D. B.; Benseler, F.; Aurup, H.; Eckstein, F. Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes Science 1991, 253, 314-317
23. Liu, B.; Conrad, F.; Cooperberg, M. R.; Kirpotin, D. B.; Marks, J. D. Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer Cells Cancer Res. 2004, 64, 704-710
24. Burmeister, P. E.; Lewis, S. D.; Silva, R. F.; Preiss, J. R.; Horwitz, L. R.; Pendergrast, P. S.; McCauley, T. G.; Kurz, J. C.; Epstein, D. M.; Wilson, C. Direct In Vitro Selection of a 2-O-Methyl Aptamer to Vegf Chem. Biol. 2005, 12, 25-33
25. Cadwell, R. C.; Joyce, G. F. Randomization of Genes by PCR Mutagenesis PCR Methods Appl. 1992, 2, 28-33
26. Zhang, L.; Chan, J. M.; Gu, F. X.; Rhee, J. W.; Wang, A. Z.; Radovic-Moreno, A. F.; Alexis, F.; Langer, R.; Farokhzad, O. C. Self-Assembled Lipid-Polymer Hybrid Nanoparticles: A Robust Drug Delivery Platform ACS Nano 2008, 2, 1696-1702
27. Chan, J. M.; Zhang, L.; Yuet, K. P.; Liao, G.; Rhee, J. W.; Langer, R.; Farokhzad, O. C. PLGA-Lecithin-PEG Core-Shell Nanoparticles for Controlled Drug Delivery Biomaterials 2009, 30, 1627-1634
28. Chan, J. M.; Zhang, L.; Tong, R.; Ghosh, D.; Gao, W.; Liao, G.; Yuet, K. P.; Gray, D.; Rhee, J. W.; Cheng, J. et al. Spatiotemporal Controlled Delivery of Nanoparticles to Injured Vasculature Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 2213-2218
29. Wu, C. C. N.; Castro, J. E.; Motta, M.; Cottam, H. B.; Kyburz, D.; Kipps, T. J.; Corr, M.; Carson, D. A. Selection of Oligonucleotide Aptamers with Enhanced Uptake and Activation of Human Leukemia B Cells Hum. Gene Ther. 2003, 14, 849-860
30. Perera, R. M.; Zoncu, R.; Johns, T. G.; Pypaert, M.; Lee, F. T.; Mellman, I.; Old, L. J.; Toomre, D. K.; Scott, A. M. Internalization, Intracellular Trafficking, and Biodistribution of Monoclonal Antibody 806: A Novel Anti-Epidermal Growth Factor Receptor Antibody Neoplasia 2007, 9, 1099-1110
31. Nguyen, H. M.; Cahill, C. M.; McPherson, P. S.; Beaudet, A. Receptor-Mediated Internalization of [3h]-Neurotensin in Synaptosomal Preparations from Rat Neostriatum Neuropharmacology 2002, 42, 1089-1098
32. Larkin, S. E.; Zeidan, B.; Taylor, M. G.; Bickers, B.; Al-Ruwaili, J.; Aukim-Hastie, C.; Townsend, P. A. Proteomics in Prostate Cancer Biomarker Discovery Expert Rev. Proteomics 2010, 7, 93-102
33. Heppner, G. H. Tumor Heterogeneity Cancer Res. 1984, 44, 2259-2265
34. Rajan, P.; Elliott, D. J.; Robson, C. N.; Leung, H. Y. Alternative Splicing and Biological Heterogeneity in Prostate Cancer Nat. Rev. Urol. 2009, 6, 454-460
35. O'Keefe, D. S.; Bacich, D. J.; Heston, W. D. Comparative Analysis of Prostate-Specific Membrane Antigen (PSMA) versus a Prostate-Specific Membrane Antigen-like Gene Prostate 2004, 58, 200-210
36. Liu, H.; Moy, P.; Kim, S.; Xia, Y.; Rajasekaran, A.; Navarro, V.; Knudsen, B.; Bander, N. H. Monoclonal Antibodies to the Extracellular Domain of Prostate-Specific Membrane Antigen Also React with Tumor Vascular Endothelium Cancer Res. 1997, 57, 3629-3634
37. Chang, S. S.; Reuter, V. E.; Heston, W. D. W.; Bander, N. H.; Grauer, L. S.; Gaudin, P. B. Five Different Anti-Prostate-Specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-Associated Neovasculature Cancer Res. 1999, 59, 3192-3198
38. Gu, F.; Zhang, L.; Teply, B. A.; Mann, N.; Wang, A.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Precise Engineering of Targeted Nanoparticles by Using Self-Assembled Biointegrated Block Copolymers Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 2586-2591
39. Istomin, Y. P.; Zhavrid, E. A.; Alexandrova, E. N.; Sergeyeva, O. P.; Petrovich, S. V. Dose Enhancement Effect of Anticaner Drugs Associated with Increased Temperature in Vitro Exp. Oncol. 2008, 30, 56-59
40. Fizazi, K.; Sikes, C. R.; Kim, J.; Yang, J.; Martinez, L. A.; Olive, M. C.; Logothetis, C. J.; Navone, N. M. High Efficacy of Docetaxel with and without Androgen Deprivation and Estramustine in Preclinical Models of Advanced Prostate Cancer Anticancer Res. 2004, 24, 2897-2903
41. Takara, K.; Sakaeda, T.; Yagami, T.; Kobayashi, H.; Ohmoto, N.; Horinouchi, M.; Nishiguchi, K.; Okumura, K. Cytotoxic Effects of 27 Anticancer Drugs in HeLa and Mdr1-Overexpressing Derivative Cell Lines Biol. Pharm. Bull. 2002, 25, 771-778